Rigel Pharmaceuticals | RIGL - Cash And Equivalent


Rigel Pharmaceuticals reported $48.53M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agenus USD 3.46M 6.08M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Anika Therapeutics USD 57.48M 509K Dec/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Celldex Therapeutics USD 28.87M 7.17M Dec/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Intrexon USD 9.34M 1.77M Jun/2024
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Ligand Pharmaceuticals USD 174.93M 489.59M Dec/2025
MacroGenics USD 57.22M 22.91M Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Veracyte USD 362.58M 47M Dec/2025